The FDA recently removed non-ambulatory Duchenne patients from the gene therapy's indication, which Sarepta hopes to have reinstated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback